Drug Trial Radar · NCT03810664
A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations
Last checked: Nov 20, 2026Latest source record: Apr 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jan 18, 2019
Primary completion
Apr 19, 2019
Study completion Apr 19, 2019
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-center, open-label randomized, 2×2 crossover (Ref Test \| Test Ref) study with a washout of two weeks to establish bioequivalence between single dose of somatrogon in a PEN to somatrogon in VIAL administered sc in healthy male volunteers.
Conditions
- Healthy Male Volunteers
Interventions
SomatrogonDrug
A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve (AUC) of the serum concentration-time from time 0 to a specific time (AUCt)Time frame: 30 days
- Area under the curve (AUC) of the serum concentration-time from time 0 to infinity (AUC∞)Time frame: 30 days
- Serum concentration from of maximum concentration (Cmax) of somatrogon levels in serumTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS Miami Research Associates
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.